399 related articles for article (PubMed ID: 28430748)
1. Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.
Dubischar KL; Kadlecek V; Sablan JB; Borja-Tabora CF; Gatchalian S; Eder-Lingelbach S; Kiermayr S; Spruth M; Westritschnig K
Pediatr Infect Dis J; 2017 Sep; 36(9):898-904. PubMed ID: 28430748
[TBL] [Abstract][Full Text] [Related]
2. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO
Jelinek T; Cromer MA; Cramer JP; Mills DJ; Lessans K; Gherardin AW; Barnett ED; Hagmann SHF; Askling HH; Kiermayr S; Kadlecek V; Eder-Lingelbach S; Taucher C; Dubischar KL
Travel Med Infect Dis; 2018; 22():18-24. PubMed ID: 29549036
[TBL] [Abstract][Full Text] [Related]
4. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
6. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
Cramer JP; Dubischar K; Eder S; Burchard GD; Jelinek T; Jilma B; Kollaritsch H; Reisinger E; Westritschnig K
Vaccine; 2016 Aug; 34(38):4579-4585. PubMed ID: 27460550
[TBL] [Abstract][Full Text] [Related]
8. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
[TBL] [Abstract][Full Text] [Related]
9. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
[TBL] [Abstract][Full Text] [Related]
10. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
[TBL] [Abstract][Full Text] [Related]
12. Product review on the JE vaccine IXIARO.
Firbas C; Jilma B
Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study.
Taucher C; Barnett ED; Cramer JP; Eder-Lingelbach S; Jelinek T; Kadlecek V; Kiermayr S; Mills DJ; Pandis D; Reiner D; Dubischar KL
Travel Med Infect Dis; 2020; 34():101616. PubMed ID: 32156630
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients.
Assawawiroonhakarn S; Apiwattanakul N; Pakakasama S; Hongeng S; Anurathapan U; Yoksan S; Klinmalai C; Sae-Chew P; Techasaensiri C
Pediatr Infect Dis J; 2021 Mar; 40(3):264-268. PubMed ID: 33427799
[TBL] [Abstract][Full Text] [Related]
15. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Fischer M; Lindsey N; Staples JE; Hills S;
MMWR Recomm Rep; 2010 Mar; 59(RR-1):1-27. PubMed ID: 20224546
[TBL] [Abstract][Full Text] [Related]
16. Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study.
Taucher C; Kollaritsch H; Dubischar KL
Vaccine; 2019 May; 37(19):2529-2531. PubMed ID: 30962094
[TBL] [Abstract][Full Text] [Related]
17. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
20. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C
J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
